MyFinsight
Home
Blog
About
Contact
Download
Download image
TRIKAFTAKAFTRIO
$10,312,700K
(0.72%↑ Y/Y)
ALYFTREK
$837,800K
Manufactured Product Other
$820,100K
(4.94%↑ Y/Y)
Product
$11,970,600K
Collaborativeand Royalty
$30,700K
Product revenues, net
$12,001,300K
(8.90%↑ Y/Y)
Income (loss) from
operations
$4,173,300K
(1891.88%↑ Y/Y)
Interest income
$490,900K
(-17.92%↓ Y/Y)
Total costs and
expenses
$7,828,000K
(-30.44%↓ Y/Y)
Income before
provision for income taxes
$4,643,200K
(1768.49%↑ Y/Y)
Interest expense
$13,300K
(-56.54%↓ Y/Y)
Other expense, net
-$7,700K
(91.06%↑ Y/Y)
Research and development
expenses
$3,909,500K
(7.69%↑ Y/Y)
Selling, general and
administrative expenses
$1,753,100K
(19.72%↑ Y/Y)
Cost of sales
$1,651,300K
(7.89%↑ Y/Y)
Intangible asset
impairment charge
$379,000K
Acquired in-process
research and development...
$133,000K
(-97.13%↓ Y/Y)
Change in fair value of
contingent consideration
$2,100K
(520.00%↑ Y/Y)
Income (loss)
$3,953,200K
(838.09%↑ Y/Y)
Provision for income taxes
$690,000K
(-12.00%↓ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
logo-vertex-inc-svg copy-svg
VERTEX PHARMACEUTICALS INC MA (VRTX)
logo-vertex-inc-svg copy-svg
VERTEX PHARMACEUTICALS INC MA (VRTX)